BTIG analyst Ryan Zimmerman maintained a Buy rating on Integra Lifesciences (NASDAQ: IART) on October 9 and set a price target of $69. The company’s shares closed yesterday at $60.14.
Zimmerman commented:
“We hosted investor meetings with mgmt. of IART which included President & CEO for multiple days of meetings in the Midwest. Investors were interested in understanding a variety of topics, including the Codman integration, wound, nerve, and dural repair market dynamics, OTT channel changes, as well as other areas of the business. We came away with a clearer picture of IART’s progression toward a higher growth company driven by sales force productivity improvements, product registrations OUS, and a growing pipeline from Codman (a previously underfunded asset). The Street may not be as focused on much of the back-office work that has taken place at IART over FY18 but mgmt. was confident in their ability to meet FY18 organic revenue growth guidance (~5%) and grow above that in FY19 and beyond. Our incremental takeaways are below.”
According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 28.5% and a 68.2% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, OrthoPediatrics Corp, and Stryker Corporation.
Integra Lifesciences has an analyst consensus of Hold, with a price target consensus of $63.50, representing a 5.6% upside. In a report issued on October 2, Oppenheimer also assigned a Buy rating to the stock.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $67.50 and a one-year low of $41.51. Currently, Integra Lifesciences has an average volume of 690.5K.
Based on the recent corporate insider activity of 76 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical and Orthopedics and Tissue Technologies segments.
